Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -7.69% is 356% below its 5-year average of 3.00%, near the low end of its 5-year range (-7.69%–8.44%).
659.27% below its 12-month average of 1.38%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -4.09%.
RETURN ON ASSETS (ROA)
-7.69%
RETURN ON ASSETS (ROA) AVG TTM
1.38%
RETURN ON ASSETS (ROA) AVG 3Y
1.60%
RETURN ON ASSETS (ROA) AVG 5Y
3.00%
RETURN ON ASSETS (ROA) AVG 10Y
8.14%
RETURN ON ASSETS (ROA) AVG 15Y
8.66%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-659.27%
CURRENT VS 3Y AVG
-579.13%
CURRENT VS 5Y AVG
-356.05%
CURRENT VS 10Y AVG
-194.50%
CURRENT VS 15Y AVG
-188.76%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+76.17%
vs the sector median at left
Supernus Pharmaceuticals, Inc.
Market Cap
$2.49B
Return on Assets (ROA)
-7.69%
TTM Avg
1.38%
3Y Avg
1.60%
5Y Avg
3.00%
Market Cap
$2.43B
Return on Assets (ROA)
-42.79%
TTM Avg
-37.88%
3Y Avg
-40.02%
5Y Avg
-36.63%
Market Cap
$2.56B
Return on Assets (ROA)
0.00%
TTM Avg
1.47%
3Y Avg
1.04%
5Y Avg
-2.29%
Market Cap
$2.38B
Return on Assets (ROA)
-2.55%
TTM Avg
-11.61%
3Y Avg
-25.65%
5Y Avg
-35.91%
Market Cap
$2.60B
Return on Assets (ROA)
-6.16%
TTM Avg
-19.77%
3Y Avg
-17.54%
5Y Avg
-23.06%
Market Cap
$2.60B
Return on Assets (ROA)
-36.84%
TTM Avg
-27.21%
3Y Avg
-27.53%
5Y Avg
-29.44%
Market Cap
$2.37B
Return on Assets (ROA)
-33.45%
TTM Avg
-24.16%
3Y Avg
-23.12%
5Y Avg
-103.71%
Market Cap
$2.61B
Return on Assets (ROA)
-0.24%
TTM Avg
-15.97%
3Y Avg
-8.17%
5Y Avg
-3.53%
Market Cap
$2.36B
Return on Assets (ROA)
24.69%
TTM Avg
32.00%
3Y Avg
9.13%
5Y Avg
-4.32%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | $2.49B | -7.69% | 1.38% | 1.60% | 3.00% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.43B | -42.79% | -37.88% | -40.02% | -36.63% |
| Privia Health Group, Inc. (PRVA)vs › | $2.56B | 0.00% | 1.47% | 1.04% | -2.29% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.38B | -2.55% | -11.61% | -25.65% | -35.91% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.60B | -6.16% | -19.77% | -17.54% | -23.06% |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.60B | -36.84% | -27.21% | -27.53% | -29.44% |
| Disc Medicine, Inc. (IRON)vs › | $2.37B | -33.45% | -24.16% | -23.12% | -103.71% |
| Neogen Corporation (NEOG)vs › | $2.61B | -0.24% | -15.97% | -8.17% | -3.53% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 24.69% | 32.00% | 9.13% | -4.32% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.35B | -63.74% | -33.67% | -37.78% | -31.10% |
ROA
-7.7%
ROE
-10.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -2.65% |
| 2024-12-31 | 5.40% |
| 2023-12-31 | 0.10% |
| 2022-12-31 | 3.57% |
| 2021-12-31 | 3.16% |
| 2020-12-31 | 8.44% |
| 2019-12-31 | 9.74% |
| 2018-12-31 | 11.35% |
| 2017-12-31 | 13.50% |
| 2016-12-31 | 29.47% |
| 2015-12-31 | 7.43% |
| 2014-12-31 | 14.45% |
| 2013-12-31 | -83.13% |
| 2012-12-31 | -49.24% |
| 2011-12-31 | 104.23% |
| 2010-12-31 | -81.82% |
| 2009-12-31 | 0.58% |
| 2008-12-31 | -43.41% |
| 2007-12-31 | 0.00% |
